Corbus Pharmaceuticals Holdings (CRBP) Long-Term Investments (2022)

Corbus Pharmaceuticals Holdings' (CRBP) quarterly Long-Term Investments came in at $16.8 million in Q4 2022.

Corbus Pharmaceuticals Holdings (CRBP) Long-Term Investments (2022) Analysis & Trends

Corbus Pharmaceuticals Holdings' Long-Term Investments history runs 1 years deep, the most recent figure standing at $16.8 million for Q4 2022.

  • On a quarterly basis, Long-Term Investments changed N/A year-over-year to $16.8 million in Q4 2022; TTM through Dec 2022 was $16.8 million, a N/A change from a year earlier, with the FY2022 full-year figure at $16.8 million, changed N/A from the prior year.
  • Long-Term Investments was little changed at $16.8 million in Q4 2022 per CRBP's latest filing.
  • Across five years, Long-Term Investments topped out at $16.8 million in Q4 2022 and bottomed at $16.8 million in Q4 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Investments (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 505,194.89
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 5.75 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 9.79 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Corbus Pharmaceuticals Holdings 164.14 Mn 136.33 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2022 16.75 Mn